Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come
This article was originally published in PharmAsia News
Executive Summary
Australia’s Prana Biotechnology has Phase II clinical trial data on a potential Huntington’s disease therapy to sustain a surge in the share price over the past year with more possibly on the way for an Alzheimer’s therapy.